益生菌对肝脏疾病的影响:目前的体外和体外研究
Maryam Sadri1, Zahra Shafaghat1, Mona Roozbehani2
1Department of Immunology, Iran University of Medical Sciences, Tehran, Iran.
Probiotics and antimicrobial proteins
|December 31, 2024
概括
益生菌提供了一种安全,自然的方法,通过积极影响肠道微生物群和宿主免疫力来对抗肝脏疾病. 本综述探讨了它们在预防和治疗肝硬化和病毒性肝炎等疾病方面的潜力.
科学领域:
- 肝病学和微生物学
- 免疫学和胃肠道学
背景情况:
- 肝脏疾病导致全球数百万人死亡,治疗选择有限,移植率低.
- 肠肝轴和免疫系统的相互作用在肝脏疾病的发病过程中至关重要.
- 益生菌是一种非毒性,生物安全的替代传统治疗肝脏疾病的替代方案.
研究的目的:
- 审查各种肝脏疾病的益生菌管理的临床前和临床证据.
- 突出益生菌在调节肠道微生物群和与肝脏健康相关的免疫反应中的作用.
- 评估益生菌及其代谢物在肝病管理中的治疗潜力.
主要方法:
- 对现有的临床前和临床研究进行系统审查.
- 分析关于益生菌对肝病模型和患者结局影响的数据.
- 评估益生菌机制,包括微生物群调节和免疫刺激.
主要成果:
- 益生菌对肠道微生物群的组成和功能产生有益影响.
- 有证据表明,益生菌可以调节免疫反应,减少肝炎.
- 益生菌代谢物,如细菌素,对肝病相关的病原体表现出抗菌活性.
结论:
- 益生菌的管理显示承诺作为预防和治疗肝脏疾病的治疗策略.
- 需要进一步的研究来阐明针对特定肝脏疾病的最佳益生菌菌株和剂量.
- 益生菌是一种可行的补充方法,用于肝脏疾病管理的传统疗法.
相关概念视频
Liver Physiology
3.8K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.8K
Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
358
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
358
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Probiotics
296
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
296


